Chua D.T.T.Yiu H.H.-Y.Seetalarom K.Ng A.W.-Y.Kurnianda J.Shotelersuk K.Krishnan G.RUEY-LONG HONGYang M.-H.Wang C.-H.Sze W.-K.Ng W.-T.2021-03-092021-03-0920121043-3074https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864966763&doi=10.1002%2fhed.21884&partnerID=40&md5=5fd12030cdd7df100ba1da1d234bf39bhttps://scholars.lib.ntu.edu.tw/handle/123456789/551242Background Capecitabine is an oral fluoropyrimidine with single-agent activity in metastatic nasopharyngeal carcinoma (NPC). This multicenter phase II study was conducted to investigate the efficacy and safety of capecitabine plus cisplatin as a first-line treatment for metastatic NPC. Methods Patients with metastatic NPC received cisplatin 100 mg/m2 day 1 plus capecitabine 1000 mg/m2 twice daily on days 1 to 14 every 3 weeks for 6-8 cycles. The primary endpoint was overall response rate. Results Forty-four patients were enrolled; 39 patients were evaluable for efficacy. The overall response rate was 53.8% (95% confidence interval [CI], 37%-70%), including 1 complete response. Median time to tumor progression was 7.3 months (95% CI, 5.6-9.9 months) and median overall survival was 28.0 months (95% CI, 14.5 months-not reached). Common grade 3/4 adverse events were neutropenia (50%), vomiting (11%), thrombocytopenia (9%), and nausea (7%). Conclusions Capecitabine plus cisplatin is an active first-line combination in metastatic NPC that requires a short hospital stay. ? 2011 Wiley Periodicals, Inc.capecitabine; cisplatin; distant metastases; nasopharyngeal cancer; palliative chemotherapy[SDGs]SDG3capecitabine; carboplatin; cisplatin; cyclophosphamide; fluorouracil; gefitinib; gemcitabine; paclitaxel; adult; aged; anemia; anorexia; article; bone metastasis; cancer chemotherapy; cancer patient; cancer survival; cancer therapy; clinical article; constipation; diarrhea; drug efficacy; drug safety; drug tolerability; febrile neutropenia; female; hand foot syndrome; human; kidney disease; male; mucosa inflammation; multicenter study; multiple cycle treatment; nasopharynx cancer; nausea; neutropenia; open study; overall survival; priority journal; progression free survival; quality of life; sepsis; thrombocytopenia; tinnitus; treatment response; tumor growth; vomiting; Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Quality of Life; Survival Analysis; Treatment Outcome; Young Adultjournal article10.1002/hed.21884220767852-s2.0-84864966763